StonvexLoading…
StonvexStonvexStonvexCore line items from ALLY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-07-16 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $2.26B | $307.00M | $1.24B | $943.00M | $635.00M |
Operating Income | Not available | $400.00M | $1.05B | $665.00M | $152.00M |
Net Income | Not available | $319.00M | $852.00M | $525.00M | $127.00M |
EPS (Diluted) | $1.30 | $0.93 | $2.37 | $1.41 | $0.23 |
Total Assets | Not available | $197.27B | $196.00B | $191.71B | $189.47B |
Total Liabilities | Not available | $181.66B | $180.50B | $176.59B | $174.93B |
Cash & Equivalents | Not available | $9.52B | $10.03B | $10.25B | $10.59B |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 307.41M | 308.49M | 307.83M | 307.79M |